PCM
SER icon

Price Capital Management’s Serina Therapeutics SER Stock Holding History

Price Capital Management’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-636
Closed -$47K – 103
2019
Q3 		$47K Buy
+636
New +$60.3K 0.03% 87
2019
Q2 		– Sell
-3,241
Closed -$461K – 54
2019
Q1 		$461K Buy
3,241
+1,247
+63% +$182K 0.13% 19
2018
Q4 		$210K Buy
+1,994
New +$254K 0.29% 5

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Price Capital Management's SER Position: Q4 2019 in Review

Price Capital Management sold out of Serina Therapeutics (SER) in Q4 2019, closing a stake of 636 shares — an estimated $47K sold.

Price Capital Management first reported a position in SER in Q4 2018 and held it in 3 quarters. The position peaked at $461K in Q1 2019. 51 funds tracked by Wall St. Rank hold SER as of Q4 2019.

  • Price Capital Management reported no remaining Serina Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Price Capital Management sold 636 Serina Therapeutics shares in Q4 2019, an estimated $47K.
  • Price Capital Management first reported a position in Serina Therapeutics in Q4 2018 and held it in 3 quarters.
  • Price Capital Management's Serina Therapeutics position peaked at $461K in Q1 2019.
  • 51 funds tracked by Wall St. Rank held Serina Therapeutics as of Q4 2019.

Based on Price Capital Management's 13F filing for Q4 2019, filed 16 Jan 2020.